1. Home
  2. KNDI vs MNOV Comparison

KNDI vs MNOV Comparison

Compare KNDI & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.85

Market Cap

67.8M

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.44

Market Cap

66.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
MNOV
Founded
2002
2000
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.8M
66.9M
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
KNDI
MNOV
Price
$0.85
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
175.5K
50.6K
Earning Date
04-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$0.78
$1.17
52 Week High
$1.77
$1.96

Technical Indicators

Market Signals
Indicator
KNDI
MNOV
Relative Strength Index (RSI) 42.45 51.45
Support Level $0.79 $1.40
Resistance Level $1.17 $1.60
Average True Range (ATR) 0.05 0.06
MACD -0.00 0.01
Stochastic Oscillator 27.81 43.52

Price Performance

Historical Comparison
KNDI
MNOV

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: